VistaGen Therapeutics Inc logo

VistaGen Therapeutics Inc

$ 0.15 -0.0109 (-6.73%) 10:08 PM EST
P/E:
At Loss
P/B:
0.67
Market Cap:
$ 31.25M
Enterprise V:
$ -14.50M
Volume:
5.81M
Avg Vol (2M):
15.76M
Volume:
5.81M
Market Cap $:
31.25M
PE Ratio:
At Loss
Avg Vol (2-Month):
15.76M
Enterprise Value $:
-14.50M
PB Ratio:
0.67
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Name Current Vs Industry Vs History
Cash-To-Debt 13.06
Equity-to-Asset 0.78
Debt-to-Equity 0.09
Debt-to-EBITDA -0.07
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -7.66
Distress
Grey
Safe
Beneish M-Score 15.15
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 14.05
9-Day RSI 28.71
14-Day RSI 33.26
6-1 Month Momentum % -83.92
12-1 Month Momentum % -93.3

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.16
Quick Ratio 6.16
Cash Ratio 5.82

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -69.2

Financials (Next Earnings Date:2022-11-10 Est.)

VTGN's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:VTGN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.065
EPS (TTM) ($) -0.31
Beta 0.68
Volatility % 89.37
14-Day RSI 33.26
14-Day ATR ($) 0.026225
20-Day SMA ($) 0.17907
12-1 Month Momentum % -93.3
52-Week Range ($) 0.1388 - 2.935
Shares Outstanding (Mil) 206.84

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

VistaGen Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

VistaGen Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.